MBX BIOSCIENCES INC (MBX)
Health Care · biotechnology · NASDAQ
MBX Biosciences is a clinical-stage biotechnology company developing precision peptide therapies to address significant unmet medical needs in endocrine and metabolic diseases.
What MBX BIOSCIENCES INC does
MBX Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of precision peptide therapeutics. The company utilizes its proprietary platform to design and engineer peptide candidates that optimize pharmacokinetic and pharmacologic properties for the treatment of endocrine and metabolic disorders.
Themes: peptide therapeutics, endocrine disorders, metabolic diseases, drug discovery platform
Fundamentals
- Price$66.33 as of 2026-08-21 close
- Market cap$3.2B as of 2026-08-21
- 1-year return+368.8% 2025-08-21 close $14.15 → 2026-08-21 close $66.33
- P/En/a earnings data not available
- ROE-26.0% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.41 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How MBX compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
MBX is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
64.2 #73 of 1,704 scored · #23 of 240 in Health Care
Trend 76th: a strong uptrend, with buyers in control; setup 74th: day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move; weakest is catalysts 50th: analysts' average price target is unchanged from the prior reading.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How MBX BIOSCIENCES INC looks technically
MBX BIOSCIENCES INC (MBX) is trading 74.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 237 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 14 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 74.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +74.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $58.75 | $58.75 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $38.11 | $38.11 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 65.01. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 237 trading days ago — a "golden cross", a bullish long-term signal | 237 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control | 31.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 55.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($64.50 to $72.64) — its "stochastic" reading is 22 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 22.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 28 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $72.64 | $72.64 |
|---|---|---|
| From the 52-week high | it is 8.7% below its 52-week high (its highest price of the past year) | -8.7% |
| Above the 52-week low | it is 588.8% above its 52-week low (its lowest price of the past year) | +588.8% |
| Below the 52-week high | it is 8.7% below its highest point of the past year | 8.7% |
| Since a 20-day breakout | it made a new 20-day high about 14 trading days ago | 14 sessions |
| Since a 55-day breakout | it made a new 55-day high about 14 trading days ago | 14 sessions |
| All-time high | its highest closing price on record is $72.64 (set on 2026-08-05) | $72.64 |
| Given back of the 52-week move | over the past year its closes ranged ($9.74 to $70.70), and it has given back only a small part of its rise from last year’s low — 7% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $31.08 to $33.03. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 7.2% |
| From the all-time high | it is 8.7% below its all-time high | -8.7% |
| Nearest price level | it is trading 37.9% above a support level at $41.18 — a price it turned at twice since 2026-02-04, most recently on 2026-02-18. Since 2024-09-13 it has 10 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -37.9% |
| All-time low | its lowest closing price on record is $4.81 (set on 2025-04-07) | $4.81 |
| Above the all-time low | it is 1279.9% above its all-time low | +1,280% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 0th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.75 between its high and its low — about 5.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.75 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $61.57 and $71.01 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $61.57 – $66.29 – $71.01 |
| Typical daily range (% of price) | its price moves about 5.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.7% |
| Stretch from the 200-day average | it is trading 7.5 daily ranges above its 200-day average price (74.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.79× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 2.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +2.3% |
|---|---|---|
| Open gap | it gapped 2.9% above the previous close 17 sessions ago and has not traded back through the level it left behind at 60.06 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.9% |
| Gap filled | a 2.3% gap up opened on 2026-08-21 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened it | today |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -3.03% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 7.7 percentage points (the stock gained 10.0% while the market gained 2.3%) | +7.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 105.6 percentage points (the stock gained 108.7% while the market gained 3.1%) | +105.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 79.6 percentage points (the stock gained 90.7% while the market gained 11.1%) | +79.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 348.3 percentage points (the stock gained 368.8% while the market gained 20.5%) | +348.3% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 24% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 9.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +24.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 56% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $42.58 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | +55.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $67.22 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -1.3% |
Price levels it has turned at before
MBX last closed at $66.33 on 2026-08-21. Since 2024-09-13 it has turned at 10 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $41.18 | Support | 37.9% below the last close | turned there twice · 2026-02-04 to 2026-02-18 |
| $35.05 | Support | 47.2% below the last close | turned there four times · 2025-11-28 to 2026-04-17 |
| $27.67 | Support | 58.3% below the last close | turned there three times · 2024-11-06 to 2026-04-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $65.01.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $85.14 and $97.58 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $65.01.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · in a Bollinger Band volatility squeeze · in a strong, established uptrend (ADX) · beating the market · Stretched far above its 200-day average (6+ daily ranges) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · bollinger bands
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.18 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$88.40 range $70.00 – $121.00; median $88.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MBX
- Consensus EPS estimate-$0.8447 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on the success of early-stage clinical trials and the high risk of failure in drug development.","Significant capital requirements and dependence on external financing to fund research, development, and operations.","Dependence on third-party manufacturers and clinical research organizations for the execution of clinical trials and production of candidates."]
What changed in the latest 10-Q
AI-assisted comparison of MBX's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to 2025 Annual Report filed March 12, 2026 (newer filing references 2025 year-end vs. older filing's 2024 year-end reference)
- Added phrase 'and commercialization' to company focus description
- Added statement that End of Phase 2 meeting with FDA and Scientific Advice with EMA were 'completed' in Q1 2026 (newer) vs. 'expected to conduct' in Q1 2026 (older)
- Added statement 'and report one-year follow-up data from our ongoing open-label extension study during the Endocrine Society's ENDO 2026 annual meeting in June 2026' for canvuparatide
- Added statement 'Beyond MBX 4291, we have a robust discovery pipeline including multiple programs in the lead optimization stage of development, and we expect to nominate two additional candidates in the second and third quarters of 2026'
- Added detailed description of imapextide Phase 1 trial design elements (SAD/MAD cohort details with dosing amounts and participant allocation)
- Removed:
- Removed detailed Phase 1 trial methodology for imapextide (specific dose amounts, cohort structures, and participant allocations)
- Removed cautionary statements about MBX 4291 preclinical studies: 'During our preclinical studies, the concentration of the active component of MBX 4291 was significantly lower than the concentration of tirzepatide during the comparison period. Although we believe MBX 4291 has the potential to be dosed less frequently, less frequent dosing would require a higher dose of MBX 4291' and 'In addition, the study supporting potential duration of MBX 4291 was conducted separately from studies evaluating its effects.'
- Removed reference to 'thirty participants' in Phase 1 trial (changed to '30 participants')
- Reworded:
- Changed 'discovery and development' to 'discovery, development and commercialization' for company focus
- Changed canvuparatide description from 'chronic hypoparathyroidism, ("HP")' to 'chronic hypoparathyroidism ("HP")' (punctuation adjustment)
- Changed 'We expect to conduct both an End of Phase 2 meeting' to 'We completed an End of Phase 2 meeting' (status change from future to completed)
- Changed presentation plans from 'present results from our Phase 2 clinical trial at a medical meeting in the second quarter of 2026; report one-year results' to 'present results from our Phase 2 clinical trial and report one-year follow-up data from our ongoing open-label extension study during the Endocrine Society's ENDO 2026 annual meeting in June 2026'
- Changed MBX 4291 description from 'PEP GLP-1 and glucose-dependent' to 'PEP GLP-1 / glucose-dependent' (formatting of co-agonist terminology)
- Changed 'receptor co-agonist' to 'co-agonist' in MBX 4291 description
- Changed 'once monthly' to 'once-monthly' (hyphenation)
- Removed 'thirty' and standardized to '30' for participant count
- Changed 'glucagon-like peptide-1' to 'glucagon-like peptide 1' (removed hyphens after 1) for imapextide description
- Notes:
- The older filing text ends mid-sentence for imapextide description ('Imapextide was generally well-'), potentially truncating comparison of that section
- Newly added discussion about nominating two additional candidates in Q2-Q3 2026 appears as forward-looking statement not present in older filing
Risk Factors
- Reworded:
- Older filing (2025-11-06) references 'on the Company' in forward-looking statements regarding geopolitical developments; newer filing (2026-05-07) changes this to 'on us'
- Notes:
- Table of contents page numbers differ between filings (Risk Factors listed as page 29 in newer vs page 31 in older; subsequent items also differ in page numbers)
- Balance sheet dates differ (March 31, 2026 vs September 30, 2025 in newer vs older respectively), reflecting different quarterly reporting periods
- Comparison limited to the forward-looking statements section and table of contents; actual Risk Factors Item 1A content not provided in either filing excerpt
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($24335) — 1 selling insider
- Last 90 days0 buys · 1 sell ($24335) — 1 selling insider
- Last 180 days0 buys · 5 sells ($3M) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-04. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MBX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding MBX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 7,633,331
- Reported value $227,854,930
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 0 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
MBX had 5,188,562 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
MBX had 10.8% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.52 days to cover at the same settlement.
- Reported short interest (shares) 5,188,562
- Short interest (% of shares outstanding) 10.8%
- Prior settlement (shares) 5,776,709
- Reported change -10.18%
- Days to cover (reported) 8.52
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Frequently asked questions
What does MBX BIOSCIENCES INC (MBX) do?
MBX Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of precision peptide therapeutics. The company utilizes its proprietary platform to design and engineer peptide candidates that optimize pharmacokinetic and pharmacologic properties for the treatment of endocrine and metabolic disorders.
What sector is MBX BIOSCIENCES INC (MBX) in?
MBX BIOSCIENCES INC (MBX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Is MBX BIOSCIENCES INC (MBX) overbought or oversold right now?
MBX BIOSCIENCES INC (MBX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MBX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.